Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
15.38
-0.12 (-0.77%)
At close: Jun 23, 2026, 4:00 PM EDT
15.08
-0.30 (-1.95%)
After-hours: Jun 23, 2026, 4:44 PM EDT
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
$807,210
Profits / Employee
-$1,165,062
Market Cap
1.95B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | 83 | -19 | -18.63% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Lakefront Biotherapeutics NV | 558 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 307 |
| Harmony Biosciences Holdings | 293 |
| Viridian Therapeutics | 252 |
| Kardigan | 241 |
| Stoke Therapeutics | 170 |
MESO News
- 5 days ago - ASX 200 Climbs as Biotech and Mining Stocks Lead Gainers on June 18, 2026 - International Business Times (Australia)
- 21 days ago - Mesoblast Slides: Investor presentation - Filings
- 7 weeks ago - Mesoblast (MESO) Reports Strong Q1 Sales for Ryoncil® - GuruFocus
- 7 weeks ago - Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - GlobeNewsWire
- 7 weeks ago - Mesoblast Earnings release: Q3 2026 - Filings
- 7 weeks ago - Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewsWire
- 2 months ago - Mesoblast acquires chimeric antigen receptor platform technology - TheFly
- 2 months ago - Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products - GlobeNewsWire